Private equity & dental investors

Understand reimbursement quality before you underwrite the deal.

Go beyond headline revenue. Screen payer economics, compare targets using available evidence, and model value-creation opportunities with explicit assumptions—not invented EBITDA upside.

Request a Demo See how it works

The decision

Why reimbursement intelligence matters

Two practices with similar collections can have very different contracted rates, participation exposure, and opportunity for change. Those differences matter in acquisitions and portfolio planning.

Bring dental reimbursement diligence into investment screening, quality-of-earnings conversations, and the value-creation plan.

What you can investigate

Make the next move with better evidence.

Underwrite current rate position

Compare disclosed negotiated rates with target-supplied payer and procedure evidence, where available.

Identify payer and network risks

Flag payer concentration, leased-network questions, and contract portability issues for diligence.

Model scenario upside

Convert validated fee schedule gaps into volume-based scenarios while separating potential from realized EBITDA.

Questions that matter

Start with the decision, not the dashboard.

PayorMap helps structure the research and evidence. Every conclusion must match the coverage and quality of the underlying observations.

Where are the target's rates positioned versus comparable local market evidence?

Do network or contracting terms create earnings fragility after closing?

Which negotiated rate scenarios are credible—and which assumptions are still missing?

An evidence-first workflow

From market data to the next step.

Choose the target and footprint

Define geography, entity/TIN mapping, payer mix, and relevant production codes.

Test market comparability

Inspect disclosed rates, sources, source dates, sample size, and provider affiliations.

Bridge to target economics

Add actual fee schedules, production and volume data, and documented implementation assumptions.

Prioritize diligence

Distinguish confirmed facts, modeled opportunity, unresolved risk, and post-close action items.

Example scope

Acquisition reimbursement diligence brief

A possible assessment structure—not a pre-generated report or a guarantee every data field exists in every market.

Discuss your assessment

Know the limits

Frequently asked questions

Can public rate files establish a target's EBITDA upside?

No. Reported rates do not establish actual target contracts, utilization, patient mix, collectability, margin, or the ability to secure improved terms. Those inputs must be independently verified.

Can PayorMap compare multiple portfolio companies?

Comparable views can be explored across the same payer, code and market dimensions, subject to reliable entity mapping, customer-provided data and source coverage.

See the data in context

Make your next decision evidence-led.

Tell us what you are evaluating, and we can review relevant payer, location and code coverage together.

Request a Demo